Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

Pages

55 results
1:33 PM, Jan 06, 2017  |  BC Week In Review | Company News  |  Deals

CymaBay, Kowa deal

CymaBay granted the Kowa Pharmaceuticals America Inc. subsidiary of Kowa rights in the U.S. to arhalofenate
royalties. Kowa will be responsible for development and commercialization. CymaBay will retain all rights to arhalofenate
5:43 PM, Jan 03, 2017  |  BC Extra | Company News

CymaBay grants Kowa U.S. rights to gout candidate

Pharmaceuticals America Inc. subsidiary of Kowa Co. Ltd. (Nagoya, Japan) rights in the U.S. to arhalofenate
MBX-102 ), which is in development to treat gout. CymaBay announced the news after market …
development and commercialization, including the planned Phase III program. CymaBay will retain all rights to arhalofenate
12:00 AM, Mar 02, 2015  |  BC Week In Review | Clinical News  |  Clinical Results

Arhalofenate: Phase IIb data

3 flares in the last 12 months showed that 800 mg once-daily oral arhalofenate
at week 12 vs. 300 mg once-daily allopurinol (0.66 vs. 1.24, p=0.0056). Additionally, 800 mg arhalofenate
a flare rate of 1.13 (p=0.049). At week 12, a 600 mg dose of once-daily arhalofenate
7:03 PM, Feb 24, 2015  |  BC Extra | Clinical News

CymaBay falls on Phase IIb gout data

19%) to $9.98 on Tuesday after reporting interim data from its Phase IIb trial of arhalofenate
MBX-102 ) to treat gout. While the trial met its primary endpoint -- with those …
12 weeks (p=0.0056) -- CymaBay said neither a 600 mg nor 800 mg dose of arhalofenate
12:00 AM, Feb 02, 2015  |  BC Week In Review | Clinical News  |  Clinical Results

Arhalofenate: Preliminary Phase II data

gout showed that 7%, 43% (p …
febuxostat and 20%, 93% (p …
40 mg febuxostat. Additionally, 31%, 88% and 94% of patients receiving once-daily 600 mg oral arhalofenate
12:00 AM, Jan 12, 2015  |  BioCentury | Finance

Buyside view XXIII: Milestones galore

radar name to watch in 2015. The biotech expects to report Phase IIb data for arhalofenate
MBX-102 ) to treat gout in 2Q15. Muijrers' other small cap pick was Neurocrine Biosciences …
12:00 AM, Oct 06, 2014  |  BC Week In Review | Clinical News  |  Clinical Status

Arhalofenate: Completed Phase IIb enrollment

patients in a double-blind, placebo-controlled, international Phase IIb trial comparing 600 and 800 mg oral arhalofenate
after a review of interim safety data. CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif.   Product: Arhalofenate
MBX-102 )   Business: Endocrine/Metabolic   Molecular target: Solute carrier family 22 organic anion urate …
12:00 AM, Jul 28, 2014  |  BioCentury | Finance

Highlights of weekly biotech stock moves

In April, the company proposed to raise up to $30 million in the offering. CymaBay's arhalofenate
MBX-102 ) is in a Phase IIb trial to treat gout, with data expected in …
5:45 PM, Jul 22, 2014  |  BC Extra | Financial News

CymaBay raises $22 million in follow-on

5.50 in a follow-on underwritten by Cowen; Stifel; Roth Capital Partners; and National Securities. CymaBay's arhalofenate
MBX-102 ) is in a Phase IIb trial to treat gout, with data expected in …
12:00 AM, Jul 21, 2014  |  BioCentury | Finance

Highlights of weekly biotech stock moves

the Form 10 pathway in October and began trading on the OTCQB in January. CymaBay's arhalofenate

Pages